ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
Cell therapy, one of the most promising frontiers in modern medicine, holds the potential to cure once-incurable diseases such as cancer and genetic disorders. But for all its promise, manufacturing ...
Stocktwits on MSN
IBRX stock rises 3% pre-market: ImmunityBio reports breakthrough in NK cell therapy production
Shares of ImmunityBio (IBRX) gained more than 3% in pre-market trading on Friday, after the pharmaceutical firm announced on Friday the completion of key manufacturing engineering programs supporting ...
Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...
GeminiBio provides serum, customized media, buffers, and process liquids to biopharma and advanced therapy companies focused on the research and production of mRNA, AAV, monoclonal antibody, and cell ...
- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...
In this innovation spotlight, Tia Harmon, technical science liaison, CGT for PHC Corporation of North America (PHCNA), discusses the key challenges in CGT manufacturing and how in-line monitoring ...
Hosted on MSN
Laser-based analytical platform enhances CAR T cell therapy manufacturing and effectiveness
A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor (CAR) T cells, including how they evolve during manufacturing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results